TcLand Expression Receives $1.7M to Validate Companion Dx for Rheumatoid Arthritis

The funding will be used primarily to set up a European multi-center clinical trial for the validation of a molecular test to predict non-response to anti-TNF treatment, in particular Remicade.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories